Effects of selective IKrchannel blockade by E-4031 on ventricular electro-mechanical relationship in the halothane-anesthetized dogs

European Journal of Pharmacology

Volumn 740, Issue , 2014, Pages 263-270

  Izumi Nakaseko, Hiroko ^a   Nakamura, Yuji ^a   Cao, Xin ^a   Ohara, Hiroshi ^a   Yamazaki, Yukiko ^a   Ueda, Naoya ^a   Ando, Kentaro ^a   Sugiyama, Atsushi ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

E 4031; Electro mechanical relationship; Halothane anesthetized dog; IKr; Positive inotropic action; QT prolongation

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ANTIARRHYTHMIC AGENT; DELAYED RECTIFIER POTASSIUM CHANNEL; HALOTHANE; INHALATION ANESTHETIC AGENT; PIPERIDINE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT; PYRIDINE DERIVATIVE;

ACTION POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; DOG; DRUG EFFECTS; FEMALE; HEART CONTRACTION; HEART OUTPUT; HEART RATE; HEART VENTRICLE; HEART VENTRICLE FUNCTION; MALE; PHYSIOLOGY;

ACTION POTENTIALS; ANESTHETICS, INHALATION; ANIMALS; ANTI-ARRHYTHMIA AGENTS; BLOOD PRESSURE; CARDIAC OUTPUT; DELAYED RECTIFIER POTASSIUM CHANNELS; DOGS; FEMALE; HALOTHANE; HEART RATE; HEART VENTRICLES; MALE; MYOCARDIAL CONTRACTION; PIPERIDINES; POTASSIUM CHANNEL BLOCKERS; PYRIDINES; VENTRICULAR FUNCTION;

EID: 84905453194     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.06.064     Document Type: Article

References (36)

1. D.M. Bers Sources and sinks of activator calcium D.M. Bers, Excitation-Contraction Coupling and Cardiac Contractile Force second ed. 2001 Kluwer Academic Publishers Dordrecht 39 62
2. S. Chiba, and M. Tsuboi Dominant anti-vagal effect of pentobarbital on cardiac responses to intracardiac autonomic nerve stimulation in the dog Jpn. J. Pharmacol. 86 2001 248 250
3. B. Darpo The thorough QT study four years after the implementation of the ICH E14 guidance Br. J. Pharmacol. 159 2010 49 57
4. Kr) channel J. Cardiovasc. Electrophysiol. 15 2004 1302 1309 (Pubitemid 39612638)
5. Food and Drug Administration, 2005a. ICH Harmonised Tripartite Guideline, The Non-clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals S7B. Recommended for adoption at step 4 of the ICH process on 12 May 2005 by the ICH Steering Committee. ICH; http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Safety/S7B/Step4/S7B-Guideline.pdf (accessed 18.12.13.).
6. Food and Drug Administration, 2005b. ICH Harmonised Tripartite Guideline. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs E14. Recommended for adoption at step 4 of the ICH process on 12 May 2005 by the ICH Steering Committee. ICH; http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline.pdf (accessed 18.12.13.).
7. Food and Drug Administration, 2012. E14 Implementation Working Group ICH E14 Guideline: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions & Answers (R1). 2012. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Q-As-R1-step4.pdf (accessed 18.12.13.).
8. M.A. Giorgi, R. Bolaños, C.D. Gonzalez, and G. Di Girolamo QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications Curr. Drug Saf. 5 2010 54 57
9. T. Ishizaka, A. Takahara, H. Iwasaki, Y. Mitsumori, H. Kise, Y. Nakamura, and A. Sugiyama Comparison of electropharmacological effects of bepridil and sotalol in halothane-anesthetized dogs Circ. J. 72 2008 1003 1011 (Pubitemid 351879925)
10. D. Izumi, M. Chinushi, K. Iijima, S. Ahara, S. Komura, H. Furushima, Y. Hosaka, A. Sanada, N. Yagihara, and Y. Aizawa Effects of bepridil versus E-4031 on transmural ventricular repolarization and inducibility of ventricular tachyarrhythmias in the dog Pacing Clin. Electrophysiol. 33 2010 950 959
11. D. Katritsis, J. Morgan, J. Brachmann, A. Bygrave, D. O'Farrell, E. Rowland, and A.J. Gamm Electrophysiological effects of E 4031, a drug with selective class III properties, in man Pacing Clin. Electrophysiol. 20 1997 930 937 (Pubitemid 27175190)
12. K. Kimura, M. Tabo, K. Mizoguchi, A. Kato, M. Suzuki, Z. Itoh, S. Omura, and H. Takanashi Hemodynamic and electrophysiological effects of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin in a halothane-anesthetized canine model J. Toxicol. Sci. 32 2007 231 239 (Pubitemid 47403193)
13. J. Merot, F. Charpentier, J.M. Poirier, G. Coutris, and J. Weissenburger Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol Cardiovasc. Res. 44 1999 303 314 (Pubitemid 29474093)
14. Y. Nagashima, Y. Furukawa, M. Hirose, Y. Hoyano, M. Lakhe, and S. Chiba Inhibition by E-4031 of the prolongation of the first returning cycle length after overdrive in anesthetized dog hearts J. Cardiovasc. Pharmacol. 31 1998 18 24 (Pubitemid 28027893)
15. C.A. Remme, and A.A. Wilde Late sodium current inhibition in acquired and inherited ventricular (dys)function and arrhythmias Cardiovasc. Drugs Ther. 27 2013 91 101
16. Y. Satoh, A. Sugiyama, A. Takahara, K. Chiba, and K. Hashimoto Electropharmacological and proarrhythmic effects of a class III antiarrhythmic drug nifekalant hydrochloride assessed using the in vivo canine models J. Cardiovasc. Pharmacol. 43 2004 715 723 (Pubitemid 38534073)
17. Y. Satoh, A. Sugiyama, K. Tamura, and K. Hashimoto Effects of a class III antiarrhythmic drug, dofetilide, on the in situ canine heart assessed by the simultaneous monitoring of hemodynamic and electrophysiological parameters Jpn. J. Pharmacol. 81 1999 79 85 (Pubitemid 29479058)
18. T.R.G. Stams, V.J.A. Bourgonje, H.D.M. Beekman, M. Schoenmakers, R. Van der Nagel, P. Oosterhoff1, J.M. Van Opstal, and M.A. Vos The electromechanical window is no better than QT prolongation to assess risk of torsade de pointes in the complete atrioventricular block model in dogs Br. J. Pharmacol. 171 2014 714 722
19. A. Sugiyama Sensitive and reliable proarrhythmia in vivo animal models for predicting drug-induced torsades de pointes in patients with remodelled hearts Br. J. Pharmacol. 154 2008 1528 1537
20. A. Sugiyama, H. Hashimoto, Y. Nakamura, T. Fujita, and Y. Kumagai QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation J. Clin. Pharmacol. 54 2014 446 452
21. Krchannel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes Jpn. J. Pharmacol. 88 2002 414 421 (Pubitemid 34516567)
22. A. Sugiyama, Y. Satoh, and K. Hashimoto Acute electropharmacological effects of intravenously administered amiodarone assessed in the in vivo canine model Jpn. J. Pharmacol. 87 2001 74 82 (Pubitemid 33815503)
23. M. Tabo, M. Nakamura, K. Kimura, and S. Ito QT-RR relationships and suitable QT correction formulas for halothane-anesthetized dogs J. Toxicol. Sci. 31 2006 381 390 (Pubitemid 44730418)
24. Krblockade Eur. J. Pharmacol. 507 2005 169 177 (Pubitemid 40126853)
25. J. Tamargo, R. Caballero, R. Gómez, C. Valenzuela, and E. Delpón Pharmacology of cardiac potassium channels Cardiovasc. Res. 62 2004 9 33 (Pubitemid 38326808)
26. S. Toyoshima, A. Kanno, T. Kitayama, K. Sekiya, K. Nakai, M. Haruna, T. Mino, H. Miyazaki, K. Yano, and K. Yamamoto QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals J. Pharmacol. Sci. 99 2005 459 471 (Pubitemid 44618147)
27. H.J. Van der Linde, B. Van Deuren, Y. Somers, B. Loenders, R. Towart, and D.J. Gallacher The electro-mechanical window: a risk marker for torsade de pointes in a canine model of drug induced arrhythmias Br. J. Pharmacol. 161 2010 1444 1454
28. A. Van de Water, J. Verheyen, R. Xhonneux, and R.S. Reneman An improved method to correct the QT interval of the electrocardiogram for changes in heart rate J. Pharmacol. Methods 22 1989 207 217 (Pubitemid 19275446)
29. H.M. Vargas A new preclinical biomarker for risk of torsades de pointes: drug-induced reduction of the cardiac electromechanical window Br. J. Pharmacol. 161 2010 1441 1443
30. A.A. Wallace, R.F. Stupienski 3rd, L.M. Brookes, H.G. Selnick, D.A. Claremon, and J.J. Lynch Jr Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs J. Cardiovasc. Pharmacol. 18 1991 687 695
31. J. Wang, K. Della Penna, H. Wang, J. Karczewski, T.M. Connolly, K.S. Koblan, P.B. Bennett, and J.J. Salata Functional and pharmacological properties of canine ERG potassium channels Am. J. Physiol. Heart Circ. Physiol. 284 2003 256 267
32. R. Webster, G. Allan, K. Anto-Awuakye, A. Harrison, T. Kidd, D. Leishman, J. Phipps, and D. Walker Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog Xenobiotica 31 2001 633 650 (Pubitemid 32826396)
33. J. Weissenburger, V.V. Nesterenko, and C. Antzelevitch Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia J. Cardiovasc. Electrophysiol. 11 2000 290 304 (Pubitemid 30165349)
34. E. Wettwer, G. Scholtysik, A. Schaad, H. Himmel, and U. Ravens Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters J. Cardiovasc. Pharmacol. 17 1991 480 487
35. E.H. Wood, R.L. Heppner, and S. Weidmann Inotropic effects of electric currents Circ. Res. 24 1969 409 445
36. Krblocker, on the atrioventricular node in anesthetized dog hearts Eur. J. Pharmacol. 297 1996 233 239